The biotech has a ways to go.
News & Analysis: Ocular Therapeutix
Find out how shares of these disruptive businesses could make you rich.
There are a few reasons this could be the best biotech stock you can buy at the moment.
An offering of its shares has bolstered its balance sheet.
OCUL earnings call for the period ending March 31, 2020.
Sales of Dextenza are picking up steam, and new data is around the corner.
The growing eye industry is something investors can’t ignore.
OCUL earnings call for the period ending December 31, 2018.
The company reported second-quarter 2018 financial results and an important business update.
The FDA rejected its eye-pain treatment for the second time.